Publications, Pharmaceutical

Exploring Systemic Nasal Delivery: Device & Formulation

The following excerpt provides an overview of an interview featuring Reenal Gandhi, Business Development Director for Aptar Pharma.

Nasal drug delivery is an emerging area of focus for biopharma companies due to the increasing demand for effective therapies for disorders of the central nervous system, anti-viral therapeutics, biologics, and emergency/rescue medications. These trends are driven by factors such as an increase in market references, patient preference, and unmet market need due to the types of new molecules being developed.

Nasal drug delivery also holds promise for bypassing the brain-blood barrier through neuronal transport, enabling the treatment of illnesses associated with the CNS that are poorly served by current therapeutics. The COVID-19 pandemic has further highlighted the potential of nasal delivery for anti-viral therapeutics.

Aptar Pharma is helping biopharma companies overcome the challenges of leveraging intranasal space by providing optimized device solutions and designing formulations with the right excipients to achieve target performance whilst ensuring the right fundamental properties to achieve the spray performance and tolerability in the nasal cavity. For drug products with particularly poor solubility and/or stability, dry powders may be preferable, especially for higher dosages, which are often more typical with biologics as compared to small molecules.

Aptar Pharma also has the experience and the network to help developers implement the right studies to answer the right questions that meet the associated regulatory guidance, which is correspondingly involved, and guide companies towards the most experienced partners at the right step of the journey.

For biopharma companies considering the 505(b)(2) regulatory pathway, nasal drug product development involves a specific skill set that requires attention to detail and expertise in creating a product that goes through a number of physical states (i.e. it is aerosolized). Top tips for the biopharma community include recognizing the importance of formulation skills in intranasal delivery, understanding that liquid sprays require balancing dose, stability, and spray characteristics, and that dry powders can be delivered directly to the nose without being reconstituted, reducing the risk of drug degradation during storage. Additionally, companies should focus on identifying the right excipients such as viscosity modifiers, mucoadhesives, and penetration enhancers to achieve target performance, and work with experienced partners who can help implement the right studies to meet regulatory guidance.

Learn more about “Novel Nasal Formulation & Delivery Summit”

Download Reenal Gandhi's Interview on "Exploring Systemic Nasal Delivery: Device & Formulation"
Author(s): Reenal Gandhi
20 Apr 2023

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

6 Nov 2023

Nasal Inhalation Testing: IPAC-RS Droplet Size Analysis

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
13 Oct 2023

Nasal Drug Delivery: In Vitro Anatomical Models

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
4 Aug 2023

Aptar Pharma Discusses Intranasal Drug Delivery with PharmTech

Podcasts, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
3 Jul 2023

Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 22

Request Access


Requesting access to Exploring Systemic Nasal Delivery: Device & Formulation.

  • This field is for validation purposes and should be left unchanged.
Back To Top